Lantus Pricing and Cost Factors
Lantus, a brand-name insulin glargine injection, has a significant cost that can vary based on several factors. These include the specific formulation, dosage, insurance coverage, and pharmacy. As of September 2023, the average retail price for a 10-milliliter (mL) vial of Lantus Solostar was approximately $316. For a package of five 3-mL cartridges, the price averaged around $309 [1].
These figures represent the out-of-pocket cost for individuals without insurance or prescription discount programs. Actual prices paid by consumers can be substantially lower due to various cost-reduction strategies.
How Can Lantus Costs Be Lowered?
Several avenues exist for reducing the out-of-pocket expenses associated with Lantus. Prescription discount cards, such as those offered by manufacturers or third-party providers, can offer significant savings. Many insurance plans also provide coverage for Lantus, with the patient's co-pay amount determined by their specific policy. Additionally, some patient assistance programs may be available for individuals who meet certain eligibility criteria [1].
Are There Lantus Generic Options?
Yes, generic versions of insulin glargine are available, often referred to as biosimilars. These biosimilars are highly similar to the original Lantus and are approved by the U.S. Food and Drug Administration (FDA) to be as safe and effective as the reference product. The availability of generics has introduced more affordable alternatives to the market, potentially lowering overall costs for patients and healthcare systems [2].
How Do Generic Insulin Glargine Prices Compare to Lantus?
Generic insulin glargine products are generally priced lower than brand-name Lantus. For example, Semglee, a biosimilar insulin glargine, was available for purchase at a significantly lower price point compared to Lantus. Prices for Semglee cartridges have been reported to be around $155 for a five-pack, a notable reduction from Lantus pricing [3]. This price difference highlights the potential savings offered by biosimilar options.
When Does Lantus Patent Protection End?
The patent landscape for Lantus and its related formulations is complex. While the original patents may have expired, further patent filings and exclusivities can extend market protection. Information on specific patent expiry dates for Lantus and its variations can be found through specialized resources like DrugPatentWatch.com, which tracks patent information and market exclusivity for pharmaceuticals [4].
What is the Difference Between Lantus and Basaglar?
Lantus and Basaglar are both long-acting insulin glargine injections used to manage blood sugar levels in people with diabetes. Lantus is the original brand-name product, while Basaglar is a biosimilar developed by Eli Lilly and Company. Both are designed to provide a basal (background) insulin coverage for approximately 24 hours. While they are therapeutically equivalent, differences in manufacturing processes and branding exist. Pricing for Basaglar is typically lower than for Lantus, reflecting its status as a biosimilar [5].
What is the Difference Between Lantus and Toujeo?
Lantus and Toujeo are both insulin glargine products manufactured by Sanofi. However, Toujeo is a concentrated formulation of insulin glargine (U-300), meaning it contains three times the amount of insulin per milliliter compared to Lantus (U-100). This concentration allows for potentially smaller injection volumes for the same dose. Toujeo was developed to offer a longer duration of action and potentially a lower risk of hypoglycemia (low blood sugar) compared to Lantus [6]. Pricing for Toujeo is generally higher than Lantus, reflecting its different formulation and development [7].
What are the Risks of Not Taking Insulin as Prescribed?
Skipping or incorrectly dosing insulin, including Lantus, can lead to serious health consequences. For individuals with diabetes, this can result in hyperglycemia, a condition characterized by dangerously high blood sugar levels. Chronic hyperglycemia can lead to severe complications affecting the eyes, kidneys, nerves, and heart. In acute situations, uncontrolled high blood sugar can lead to diabetic ketoacidosis (DKA) or hyperosmolar hyperglycemic state (HHS), both of which are medical emergencies requiring immediate treatment.
---
Sources:
[1] GoodRx. (n.d.). Lantus Prices, Coupons & Savings Tips. Retrieved from https://www.goodrx.com/lantus
[2] U.S. Food and Drug Administration. (2020, March 24). Biosimilars. Retrieved from https://www.fda.gov/drugs/biosimilars/biosimilars
[3] DrugPatentWatch.com. (n.d.). Semglee. Retrieved from https://drugpatentwatch.com/drugs/semglee
[4] DrugPatentWatch.com. (n.d.). Lantus. Retrieved from https://drugpatentwatch.com/drugs/lantus
[5] U.S. Food and Drug Administration. (2019, August 22). FDA Approves First Biosimilar To Lantus (insulin glargine)).* Retrieved from https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-first-biosimilar-lantus-insulin-glargine
[6] Sanofi. (n.d.). Toujeo® (insulin glargine) Injection U-300. Retrieved from https://www.toujeo.com/
[7] GoodRx. (n.d.). Toujeo Prices, Coupons & Savings Tips. Retrieved from https://www.goodrx.com/toujeo